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Abstract
Background: B cell-specific Moloney murine leukemia virus integration site 1 (Bmi-1) plays an important role in
regulating stemness in some kinds of cancer. However, the mechanisms remain unclear. This study was to
investigate whether and how Bmi-1 regulates stemness of gastric cancer.
Methods: We firstly explored the role of Bmi-1 in regulating stem cell-like features in gastric cancer. Secondly,
we screened out its downstream miRNAs and clarified whether these miRNAs are involved in the regulation of
stemness. Finally, we investigated the mechanisms how Bmi-1 regulates miRNAs.
Results: Bmi-1 positively regulates stem cell-like properties of gastric cancer and upregulates miR-21 and miR-34a.
There was a positive correlation between Bmi-1 and miR-21 expression in gastric cancer tissues. MiR-21 mediated
the function of Bmi-1 in regulating stem cell-like properties, while miR-34a negatively regulates stem cell-like
characteristics via downregulating Bmi-1. Bmi-1 binds to PTEN promoter and directly inhibits PTEN and thereafter
activates AKT. Bmi-1 also regulates p53 and PTEN via miR-21. Bmi-1 activated NF-kB via AKT and enhanced the
binding of NF-kB to the promoter of miR-21 and miR-34a and increased their expression.
Conclusions: Bmi-1 positively regulates stem cell-like properties via upregulating miR-21, and miR-34a negatively
regulates stem cell-like characteristics by negative feedback regulation of Bmi-1 in gastric cancer. Bmi-1 upregulates
miR-21 and miR-34a by activating AKT-NF-kB pathway.
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Background
Gastric cancer, with highly aggressivity, is one of com-
mon diagnosed and the leading causes of cancer death,
so novel biomarker effective therapeutic strategies are
being urgently sought [1, 2]. As an oncogene, overex-
pression of B cell-specific Moloney murine leukemia
virus integration site 1 (Bmi-1) is present in a wide var-
iety of tumors and associated with poor prognosis [3, 4].
Bmi-1 may also be involved in cancer metastasis and
treatment resistance in some kinds of cancer [5–7]. Our
previous studies have found that Bmi-1 expression in
gastric cancer is associated with lymph node metastasis
and clinical stage and is an independent prognostic
factor in patients with gastric cancer [8, 9]. Importantly,
Bmi-1 plays an essential role in maintaining self-renewal
of hematopoietic stem cells [10, 11]. It is regarded as
one of the stem cell markers and a crucial regulator of
prostate stem cell self-renewal and malignant transform-
ation [12]. In addition, it is also involved in self-renewal
of breast cancer and glioma cancer stem cells (CSCs)
[13, 14]. However, the underlying mechanisms of Bmi-1
regulating stemness remain unclear.
CSCs are a small proportion of cells with stem cell fea-
tures in tumor tissues and considered as a source of tumor
formation [15, 16]. Although CSCs only account for a very
small fraction of cancer cells, they demonstrate important
features including self-renewal, resistance to treatment,
and high metastasis potential, all of which make them the
source of cancer relapse and treatment failure [17, 18]. Re-
searchers have isolated subgroups of stem cells from many
types of tumors. The investigation on gastric CSCs was
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initiated later than that on other cancers. Scholars have
preliminarily isolated gastric CSCs or stem cell-like cells
from gastric cancer cell lines or tissues [19–22]. Takaishi
et al. conducted serum-free culture of human gastric
cancer cell lines to obtain microspheres and found
them possessing CSCs properties [19]. CD44+CD24+
and EpCAM+/CD44+ cell subgroups have also been
confirmed to have CSCs properties [21]. Recently, Chen
et al. isolated CD44+CD54+ cells subgroup from gastric
cancer tissue and peripheral blood of patients with gas-
tric cancer and found that this cell subgroup had self-
renewal ability and formed transplanted tumor which
had features very similar to those of the original tumor
[22]. All these studies have shown the existence of gastric
CSCs. Side population (SP) cells isolated from gastric can-
cer cells and gastric cancer tissues also have CSCs features
[23, 24]. Bmi-1 was found to be overexpressed in SP cells
[24]. However, there are also studies showing no increase
of Bmi-1 expression in gastric CSCs [19]. Therefore, the
results of Bmi-1 expression in gastric CSCs are still con-
flicting, and further research is required to clarify whether
Bmi-1 plays a role in regulation of stemness in gastric
cancer.
In this study, we intended to explore the role and
mechanisms of Bmi-1 in regulating stem cell-like fea-
tures of gastric cancer. Here, we show that Bmi-1 posi-
tively regulates stem cell-like properties via upregulating
miR-21, and miR-34a negatively regulates stem cell-like
characteristics by negative feedback regulation of Bmi-1
in gastric cancer.
Methods
Details regarding cell strains and cell culture methods,
vectors construction and virus infection, spheroid colony
formation assay, chemo-sensitivity experiment, cell migra-
tion assay, Western blot, immunohistochemical analyse-
s(IHC), immuno-fluorescence staining, Quantitative real
time RT-PCR (QRT-PCR), chromatin immunoprecipita-
tion(ChIP), dual fluorescence report assay, and in vivo
tumorigenesis are provided in the supplementary materials
and methods (see Additional file 1).
Clinical samples and analyses
The expression of Bmi-1 in 101 paraffin-embedded pri-
mary site specimens of gastric cancer and 72 ovarian
metastatic specimens originated from gastric cancer, and
the expression of Oct4, Sox2, Gli1, CD44, and CD133 in
101 primary site specimens of gastric cancer was tested
using IHC.
Another 74 fresh gastric cancer tissues and paired nor-
mal mucosal tissues were used to detect the expression
of Bmi-1 messenger RNA (mRNA) and miRNAs by
QRT-PCR. Details are provided in supplementary methods.
Statistics
All statistical analyses were done by using the SPSS 19.0
software package, and two-tailed P values of less than
0.05 were considered significant. In IHC assays of gastric
cancer samples, Pearson χ2 test was used to determine the
correlation between Bmi-1 expression and clinicopathologic
characteristics, and Spearman's Rank correlation assay was
used to determine the correlation between Bmi-1 and stem
cell markers expression. Among 21 pairs of samples, the
matching McNemar test was used to detect the difference
of Bmi-1 expression between primary and metastatic le-
sions. In QRT-PCR analysis of fresh tissues, the expression
of Bmi-1, miR-21, or miR-34a was not normally distributed.
Hence, the distribution was established by using Log10 and
geometric averages. The correlation between Bmi-1 and
miR-21/miR-34a expression levels was analyzed by the
Pearson coefficient test. The correlation between Bmi-1,
miR-21, or miR-34a expression and clinicopathologic char-
acteristics was analyzed by ANOVA.
Results
Bmi-1 positively regulates stem cell-like properties of
gastric cancer cells
Cultured CSCs are believed to be able to form spheres
that have stem cells properties, which are very similar to
endogenous CSCs isolated from human tumor tissues
[25, 26]. Our former research has revealed that isolated
sphere cells from gastric cancer cell lines and primary
cancer cells by serum-free culture method have stem
cell-like properties, suggesting microsphere enrich CSCs
or stem cell-like cells [27]. To clarify the role of Bmi-1
in stemness of gastric cancer, we checked the expression
of Bmi-1 in microsphere and found that sphere cells
from SGC7901 and MKN45 cell lines overexpressed
Bmi-1 and other stem cell markers Oct-4, Sox2, Nanog,
CD44, and CD133 (Fig. 1a and Additional file 2: Figure
S1). Next, we used Bmi-1 overexpression plasmids and
Bmi-1 interference plasmids to transfect SGC7901 and
MKN45 cells, respectively, so as to exogenously change
the Bmi-1 expression level. Serum-free suspension cul-
ture method was used to detect microsphere formation
rate of gastric cancer cells after changing Bmi-1 expres-
sion. CCK-8 method was used to detect the influence of
Bmi-1 on chemotherapy sensitivity of gastric cancer
cells, and Transwell Chambers as an in vitro migration
model were used to detect the effects of Bmi-1 on the
migration ability of gastric cancer cells. Results showed
that the microsphere formation rate was significantly
higher, the drug resistance to epirubicin (EPI) was in-
creased by about three times (IC50: 0.45 vs. 0.13 μg/ml),
and the cells migration ability was enhanced after over-
expressing Bmi-1 in SCG 7901 cells, when compared
with those in control cells (left panels of Fig. 1c–e). For
MKN45 cells, by contrast, the microsphere formation
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rate was decreased, chemotherapy sensitivity to EPI was
increased (IC50: 0.11 μg/ml in small interfering RNA
(siRNA) group vs. 0.28 μg/ml in control group), and cell
migration ability was suppressed after Bmi-1 interference
(right panels of Fig. 1c–e). We have also tested the in-
fluence of Bmi-1 on stem cell markers by Western blot
and found that Bmi-1 upregulated the stem cell markers in-
cluding CD44, CD133, Nanog, SOX2, and Oct-4 (Fig. 1b).
In another gastric cancer cell line AGS, we decreased Bmi-
1 expression by gene interference or overexpressed Bmi-1
and obtained similar results by the same methods (data not
shown). These results showed that Bmi-1 positively regu-
lates stem cell-like characteristics of gastric cancer cells.
In order to further verify the relationship between
Bmi-1 and stem cell-like characteristics, we used immu-
nohistochemical method to detect the expression of Bmi-1
in 101 primary site specimens of gastric cancer and 72
ovarian metastases specimens originated from gastric can-
cer (Additional file 3: Figure S2a). The results showed that
63 out of 101 primary site specimens were Bmi-1 protein
positive with a positive rate of 62.4 %, and Bmi-1 expression
positively correlated with regional lymph node metastasis
(Table 1). Among 72 ovarian metastases specimens, 57
were Bmi-1 protein positive with a positive rate of 79.2 %,
which was significantly higher than that in primary tumors
(P = 0.018). Among 21 pairs of samples for which the pri-
mary tumor and ovarian metastases were from the same
patient, 6 pairs had inconsistent expression of Bmi-1, in-
cluding 5 pairs with the ovarian metastasis showing positive
Bmi-1 and the primary tumor showing negative Bmi-1, 1
pair with the ovarian metastasis showing negative Bmi-1
and the primary tumor showing positive Bmi-1, and the
matching McNemar test demonstrated a trend of higher
expression in the metastatic site than in the primary
site (P = 0.063, Additional file 4: Table S1). We also de-
tected the expression of stem cell markers including
Oct-4, Sox-2, Glil, CD44, and CD133 in the primary sites
of gastric cancer and analyzed the correlation between
these stem cell markers and Bmi-1 by spearman rank
(See figure on previous page.)
Fig. 1 Bmi-1 positively regulates stem cell-like properties of gastric cancer cells. a Tumorigenic spheres are derived from SGC7901 gastric cancer
cell line in serum-free media containing EGF and bFGF (upper panel) and overexpressed stem cell markers including Bmi-1, Oct-4, Sox-2, Nanog,
CD44, and CD133 (lower panel). The expression of stem cell markers in the cell lysis was analyzed by Western blot. PC parental cells, SC spheroid
cells. b Bmi-1 overexpression upregulates the expression of stem cell markers Oct-4, Sox-2, Nanog, CD44, and CD133 in SGC7901 cells (left panel)
and Bmi-1 knockdown downregulates the expression of stem cell markers in MNK45 cells (right panel). The expression of Bmi-1 and stem cell
markers in the cell lysis was analyzed by Western blot. c Bmi-1 overexpression improves microsphere formation in SGC7901 cells (left panel), and
Bmi-1 knockdown inhibits microsphere formation in MNK45 cells (right panel). Microsphere formation was tested by serum-free suspension culture
(left upper panel) and quantified (left lower panel) in Bmi-1 overexpressing cells (Bmi-1) and control cells (vector) and picture of microsphere (right upper
panel) and quantified (right lower panel) in Bmi-1 knockdown cells (Bmi-1i) and control cells (Ctrli). d Bmi-1 overexpression increases drug resistance in
SGC7901 cells (IC50: 0.45 μg/ml in overexpression group vs. 0.13 μg/ml in control group, left panel) and Bmi-1 knockdown decreases drug resistance to
EPI in MNK45 cells (IC50: 0.11 μg/ml in siRNA group vs. 0.28 μg/ml in control group, right panel). Cell viability after treatment with increasing doses of
EPI for 48 h was determinated with CCK-8. e Bmi-1 overexpression promotes migration potential in SGC7901 cells (left panel), and Bmi-1 knockdown
inhibits migration ability in MNK45 cells (right panel). Migration ability of cells was detected by Transwell Assay and then photographed (upper
pane) and quantified (lower panel). Error bars in all panels represent the mean ± standard deviation (SD). (*P < 0.05, **P < 0.01 as compared
with control)
Table 1 The relation between the expression of Bmi-1 protein
and clinicopathologic variables
Variables Bmi-1(+) Bmi-1(−) P value
Lymph node metastasis
Negative 7(33.3 %) 14(66.7 %) 0.003
Positive 51(68.9 %) 23(31.1 %)
T classification
T1–3 22(57.9 %) 16(42.1 %) 0.606
T4 36(63.2 %) 21(36.8 %)
TNM staging
I 2(50 %) 2(50 %) 0.254
II 10(45.5 %) 12(54.5 %)
III 38(69.1 %) 17(30.9 %)
IV 8(57.1 %) 6(42.9 %)
Differentiation
Moderately 25(59.5 %) 17(40.5 %) 0.786
Poorly 33(62.3 %) 20(37.7 %)
Vascular invasion
Positive 39(65.0 %) 21(35.0 %) 0.302
Negative 19(54.3 %) 16(45.7 %)
Neural invasion
Positive 35(61.4 %) 22(38.6 %) 0.932
Negative 23(60.5 %) 15(39.5 %)
Age(year)
≥60 22(57.9 %) 16(42.1 %) 0.606
<60 36(63.2 %) 21(36.8 %)
Gender
Male 41(61.2 %) 26(38.8 %) 0.965
Female 17(60.7 %) 11(39.3 %)
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correlation test (Additional file 3: Figure S2b–f, and
Additional file 5: Table S2). The results showed that Bmi-1
expression was positively correlated with the expression of
the above-mentioned stem cell markers.
Bmi-1 regulates the expression of several miRNAs
Previous study has shown that the transcription factor
p53 regulates epithelial-mesenchymal transition (EMT)
and stem cell properties through modulating miRNAs
[28]. In light of this, we assumed that as an exogenous
gene-silencing factor which regulates the expression of a
variety of genes [29–31], Bmi-1 may also play its bio-
logical effects via regulating the expression of miRNAs.
To test this hypothesis, we used microRNA (miRNA) ex-
pression profile chip to detect the changes of miRNA in
gastric cancer cells after Bmi-1 knockdown. The results
showed that there were eight differentially expressed
miRNAs, in which miR-21, miR-210, miR-886-5p, miR-103,
miR-107, and miR-34a were positively regulated by the
Bmi-1, while miR-15b and miR-125-a-5p were negatively
regulated by Bmi-1. Validating through QRT-PCR, we
found three miRNAs with significantly altered expression:
miR-21, miR-34a, and miR-125-a-5p, and their expression
were all positively regulated by Bmi-1 (Fig. 2a, b).
In order to further verify the relationship between Bmi-1
and miRNAs, we used QRT-PCR method to detect Bmi-1
mRNA and miR-21, miR-34a levels in the gastric cancer tis-
sues, and corresponding normal gastric mucosa tissues
from 74 patients with gastric cancer. Pearson correlation
analysis showed that there was a positive correlation
between the expression of Bmi-1 and miR-21 (r = 0.260,
P = 0.025) as the expression of miR-21 in gastric cancer
tissues with high Bmi-1 expression was higher than that
in tissues with low Bmi-1 expression (Fig. 2c), while the
expression of miR-34a had no obvious correlation with
Bmi-1 level (r = −0.118, P = 0.318) as the expression of
miR-34a was not different in gastric cancer tissues with
high Bmi-1 expression from tissues with low Bmi-1 ex-
pression (Fig. 2d). We also analyzed the correlation be-
tween the Bmi-1, miR-21, and clinical pathological factors.
Results showed that the expression of Bmi-1 in cancer tis-
sues is upregulated in 37 cases (50 %) compared with that
in paired adjacent normal tissues (Additional file 6: Table
S3), and Bmi-1 overexpression positively correlated with
depth of invasion (T classification), vascular invasion, or
neural invasion as the expression of Bmi-1 was higher in
patients with deeper invasion, positive vascular invasion,
or neural invasion (Table 2), which suggested that overex-
pression of Bmi-1 correlated with a more aggressive
phenotype in GC. On the other hand, the expression of
miR-21 in cancer tissues is upregulated in 44 cases
(59.46 %) compared with that in paired adjacent normal
Fig. 2 Bmi-1 regulates the expression of several miRNAs. a Bmi-1 overexpression upregulates the expression of miR-21, miR-34a, and miR-125a-5p. Fold
change of miRNAs was detected by QRT-PCR in SGC7901 cells with Bmi-1 overexpression and control cells. b Bmi-1 knockdown downregulates
the expression of miR-21, miR-34a, and miR-125a-5p. Fold change of miRNAs was detected by QRT-PCR, normalized to 5S in MKN45 cells with
Bmi-1 knockdown and control cells. c Pearson correlation analysis showed there was a positive correlation between the expression level of
Bmi-1 and miR-21. The expression of miR-21 in gastric cancer tissues with high Bmi-1 expression was higher than tissues with low Bmi-1
expression. The log10 of miR-21 expression level was plotted in Bmi-1 high and Bmi-1 low groups of gastric cancer tissues. d The expression
of miR-34a was not different in gastric cancer tissues with high Bmi-1 expression from tissues with low Bmi-1 expression. The log10 of
miR-34a expression level was plotted in Bmi-1 high and Bmi-1 low groups of gastric cancer tissues. Error bars in all panels represent the mean ± SD
(*P < 0.05, **P < 0.01)
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tissues (Additional file 6: Table S3), and the expression of
miR-21 was associated with vascular invasion or differenti-
ation as the expression of miR-21 was higher in patients
with vascular invasion or poor differentiation (Table 2),
which suggested that overexpression of miR-21 correlated
with a more aggressive phenotype. These data also sug-
gested miR-21 might be a downstream effector of Bmi-1.
MiR-21 positively regulates stem cell-like characteristics
of gastric cancer cells
We intended to clarify whether Bmi-1 downstream
miRNAs is involved in the regulation of stemness in
gastric cancer cells. First of all, we investigated miR-21
which is closely related to Bmi-1.
At first, we used QRT-PCR to detect the expression of
miR-21 in suspension microspheres separated from
gastric cancer cells by serum-free culture method. The
results showed that miR-21 expression in suspension
microspheres which enrich stem-like cells increased
significantly than in the parent adherent cells (Fig. 3a).
Furthermore, we tested the influence of different miR-21
expression levels on stem cell-like characteristics and
found that miR-21 upregulation can increase the micro-
sphere formation rate, resistance to chemotherapy, and
migration ability of gastric cancer cells (Fig. 3b-d), while
miR-21 downregulation can decrease the microsphere for-
mation rate, resistance to chemotherapy, and migration
ability (Additional file 7: Figure S3a–c). We also tested the
effect of miR-21 on the expression of stem cell markers
and found that the expression of CD44, CD133, Nanog,
SOX2, and Oct-4 were increased after miR-21 overexpres-
sion in SGC7901 cells (Fig. 3f) and reduced after miR-21
downregulation in MKN45 cells (Additional file 7:
Figure S3e). These results indicated that miR-21 may posi-
tively regulate the stem cell-like characteristics of gastric
cancer cells.
Two important tumor suppressor genes PTEN and
p53 are downstream target genes of miR-21 [32, 33]. We
also tested the effect of miR-21 on these two genes. The re-
sults demonstrated that after overexpression of miR-21 in
SGC7901 cells, the expression of PTEN, and P53 was de-
creased and the expression of phosphorylated AKT (pAKT)
of the PTEN downstream was increased and total AKT had
no change (Fig. 3f); after downregulation of miR-21 in
MKN45 cells, PTEN, and P53 were increased, and pAKT
was downregulated (Additional file 7: Figure S3e).
Bmi-1 regulates stem cell-like characteristics of gastric
cancer cells via upregulation of miR-21
In order to detect whether miR-21 plays a role in the
downstream of Bmi-1, we utilized co-transfection to
simultaneously change the expression of Bmi-1 and
miR-21 in cells in an exogenous way and observed the
effects on stem cell-like properties of gastric cancer cells.
In MKN45 cells, we compared the stem cell-like charac-
teristics of the control cells, Bmi-1 gene interference
cells and cells with Bmi-1 interference, and simultaneous
overexpression of miR-21. The results showed that miR-
21 overexpression can reverse the inhibition of stem
cell-like characteristics (self-renewal ability, resistance to
chemotherapy and cell migration ability) (Fig. 4a–c) and
the downregulation of stem cell markers expression
caused by Bmi-1 knockdown (Fig. 4g). Further, miR-21
overexpression enhances in vivo tumorigenecity and
implantation metastasis of MKN45 cells which was
inhibited by Bmi-1 knockdown in SCID mice model
(Fig. 4e, f ). In SGC7901 cells, downregulation of miR-21
can inhibit the enhancement of stem cell-like characteris-
tics and the increase of stem cell markers expression
caused by Bmi-1 overexpression (Additional file 8: Figure
S4a–c, e). These results indicated Bmi-1 can regulate stem
cell-like characteristics of gastric cancer cells by upregula-
tion of miR-21.
Table 2 Correlations between the expression level of Bmi-1,
miR-21 or miR-34a, and clinical-pathologic variables
Variable Number Bmi-1 miR-21 miR-34a
GA P GA P GA P
Age(year)
≤59 40 2.246 2.066 0.449
≥60 34 2.699 0.616 2.596 0.681 0.747 0.204
Gender
Male 56 2.373 1.984 0.434
Female 18 2.682 0.774 3.608 0.351 0.619 0.449
Lymph node metastasis
Negative 30 1.717 1.988 0.679
Positive 44 3.110 0.108 2.531 0.667 0.502 0.459
T classification
T1/2/3 36 1.372 1.542 0.733
T4 38 4.223 0.001* 3.343 0.159 0.445 0.212
Vascular invasion
Negative 33 1.235 1.080 0.892
Positive 41 4.235 0.000* 4.210 0.012* 0.394 0.041*
Neural invasion
Negative 31 1.348 1.654 0.833
Positive 43 3.755 0.004* 2.905 0.313 0.430 0.101
Differentiation
Moderately 32 1.687 1.013 0.612
Poorly 42 3.243 0.074 4.278 0.008* 0.536 0.744
Staging
I/II 27 1.935 1.442 0.818
III/IV 47 2.795 0.332 2.997 0.200 0.460 0.165
GA geometrical average
*Statistically significant
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We further tested the change of miR-21 downstream
target genes and found that Bmi-1 overexpression can
downregulate p53 and PTEN, which are downstream
target genes of miR-21, and upregualte pAKT, while
simultaneous downregulation of miR-21 can restore the
expression of p53 and PTEN and downregulate pAKT
Fig. 3 miR-21 overexpression enhances stem cell-like properties of gastric cancer cells. a miR-21 is overexpressed in cancer stem-like cells of gastric
cancer. Fold change of miR-21 in spheroid cells (SC) and parental cells (PC) of SGC7901 was analyzed by QRT-PCR. b miR-21 overexpression increases
microsphere formation rate in gastric cancer cells. Microsphere formation rate was detected by serum-free culture (upper panel) and quantified (lower
panel) in miR-21 overexpressing cells (miR-21) and control cells (Con). c miR-21 overexpression increases drug resistance in SGC7901 cells. Cell viability
in miR-21 overexpressing cells (miR-21) and control cells (Con) treated with different doses of EPI for 48 h was determinated with CCK-8. d miR-21
overexpression promotes migration potential in SGC7901 cells. Migration ability of cells was detected by Transwell Assay and then photographed
(upper pane) and quantified (lower panel). e miR-21 overexpression was confirmed in SGC7901 cells after infected by lentivirus with miR-21
overexpression. Fold change of miR-21 in miR-21 overexpressing cells (miR-21) and control cells (Con) was analyzed by QRT-PCR. f miR-21
overexpression upregulates the expression of stem cell markers in SGC7901 cells. The expression of stem cell markers and known miR-21
target and downstream genes (PTEN-AKT, P53) in the cell lysis was analyzed by Western blot. Error bars in all panels represent the mean ± SD
(*P < 0.05, **P < 0.01 as compared with control)
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(Additional file 8: Figure S4e). Similarly, when Bmi-1 is
silenced, p53 and PTEN expression are upregulated,
and pAKT is downregulated, while overexpression of
miR-21 at the same time can inhibit the upregulation
of p53 and PTEN and the downregulation of pAKT
caused by Bmi-1 silence (Fig. 4g). These results further
confirm that Bmi-1 regulates the expression of miR-21
and its downstream target genes and pathways.
MiR-34a negatively regulates stem cell-like characteristics
of gastric cancer cells
MiR-34a plays a role of tumor suppressor in other types
of tumors [34, 35]. As we found Bmi-1 upregulates miR-
34a in gastric cancer cells, here, we explored the function
of miR-34a in gastric cancer. Firstly, we found the expres-
sion of miR-34a was downregulated in all six gastric cancer
cell lines compared with that in human gastric mucosal
epithelial cell line GES-1 (Additional file 9: Figure S5a),
and it was also downregulated in suspension microspheres
than in the parent adherent cells (Fig. 5a). Overexpression
of miR-34a inhibited cells growth and colony formation
(Fig. 5b, c), suggesting it may act as a tumor suppressor.
Further, we examined the effect of different expression
levels of miR-34a on stem cell-like characteristics and
found that upregulation of miR-34a may suppress the for-
mation rate of the microspheres of gastric cancer cells, re-
sistance to chemotherapy and cell migration (Fig. 5d–f),
while downregulation of miR-34a can improve the forma-
tion of microspheres, chemotherapy resistance, and cell
migration (Additional file 9: Figure S5b–d). Further, we an-
alyzed the expression of miR-34a in 74 patients with gastric
cancer. Results showed that the expression of miR-34a in
cancer tissues is downregulated in 35 cases (47.3 %)
compared with that in paired adjacent normal tissues
(Additional file 6: Table S3), and miR-34a expression
negatively correlated with vascular invasion as the ex-
pression of miR-34a was lower in patients with positive
vascular invasion (Table 2), which suggested that down-
regulation of miR-34a correlated with a more aggressive
phenotype. These results suggest that miR-34a might act
as a tumor suppressor and negatively regulates stem cell-
like characteristics in gastric cancer.
MiR-34a negatively regulates stem cell-like characteristics
of gastric cancer cells by downregulating Bmi-1
In the above-mentioned study, we found that Bmi-1 can
upregulate the expression of miR-34a, but the function
of Bmi-1 in regulating the stem cell-like characteristics
is in contrary to that of miR-34a. How to explain this
phenomenon? We assumed there might be a negative
feedback pathway and Bmi-1 may inhibit its own function
by this pathway. We used several software to predict
miR-34a target gene. Bmi-1 was not among the predicted
target genes, but Myc appeared to be its target gene. Previ-
ous research also showed that c-Myc was a target gene of
miR-34 [36, 37]. We previously found that c-Myc can bind
to Bmi-1 promoter and increase the expression of Bmi-1
[38]. Therefore, miR-34a may theoretically downregualte
Bmi-1 via c-Myc. We examined the effect of miR-34a on
c-Myc and Bmi-1 and found that after upregulation of
miR-34a, the expression of both Bmi-1 and c-Myc was
suppressed, while overexpression of c-Myc may increase
the inhibited expression of Bmi-1, suggesting that
miR-34a may downregulate Bmi-1 through targeting
c-Myc (Fig. 6a).
To determine whether miR-34a plays a role via Bmi-1,
we used the co-transfection method to simultaneously
change the expression of Bmi-1 and miR-34a in an ex-
ogenous way and observe the effect on characteristics of
gastric cancer stem cells. In AGS and MKN45 cells, we
compared stem cell-like characteristics of the control
cells, miR-34a overexpressing cells, and cells simultan-
eously overexpressing Bmi-1 and miR-34a and found
that overexpression of Bmi-1 can reverse the inhibition
of stem cell-like characteristics (colony and microsphere
formation, cell migration and resistance to chemotherapy)
induced by miR-34a upregulation (Fig. 6b–e). These re-
sults suggested that miR-34a negatively regulates stem
(See figure on previous page.)
Fig. 4 miR-21 overexpression restores stem cell-like characteristics of gastric cancer cells which were inhibited by Bmi-1 knockdown. a miR-21
overexpression restores microsphere formation of Bmi-1 knockdown MKN45 cells. Microsphere formation in control cells (Ctrli), Bmi-1 gene interference
cells (Bmi-1i), and cells with Bmi-1 interference and simultaneous overexpression of miR-21 (Bmi-1i+miR-21) was detected by serum-free suspension
culture (upper panel) and quantified (lower panel). b miR-21 overexpression increases drug resistance in MKN45 cells which was inhibited by
Bmi-1 knockdown. Cell viability in Ctrli, Bmi-1i, and Bmi-1i+miR-21 MKN45 cells treated with different doses of EPI for 48 h was determinated
with CCK-8 method. c miR-21 overexpression enhances migration ability in MKN45 cells which was inhibited by Bmi-1 knockdown. Migration
ability in Ctrli, Bmi-1i, and Bmi-1i+miR-21 MKN45 cells was tested by Transwell migration assay. d miR-21 overexpression in Bmi-1 knockdown
MKN45 cells was confirmed by QRT-PCR. Fold change of miR-21 in Ctrli, Bmi-1i, and Bmi-1i+miR-21 MKN45 cells was determinated by QRT-PCR.
e miR-21 overexpression enhances tumorigenecity in MKN45 cells which was inhibited by Bmi-1 knockdown. In vivo tumorigenecity in Ctrli, Bmi-1i,
and Bmi-1i+miR-21 MKN45 cells was detected by subcutaneously cancer cells injected SCID mice model. f miR-21 overexpression enhances
implantation metastasis of MKN45 cells which was inhibited by Bmi-1 knockdown. In vivo implantation metastasis potential in Ctrli, Bmi-1i,
and Bmi-1i+miR-21 MKN45 cells was detected by intraperitoneal cancer cells injected SCID mice model. g miR-21 overexpression restores the
expression of stem cell markers and miR-21 target genes (PTEN, P53) in Bmi-1 knockdown MKN45 cells. The expression of Bmi-1, stem cell
markers and miR-21 target genes (PTEN-AKT, P53) in Ctrli, Bmi-1i and Bmi-1i+miR-21 MKN45 cells was analyzed by Western blot. Error bars in
all panels represent the mean ± SD (*P < 0.05, **P < 0.01)
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cell-like characteristics of gastric cancer cells by negative
feedback regulation of Bmi-1.
Bmi-1 regulates the expression of miR-21 and miR-34a via
NF-kB
As Bmi-1 is a gene-silencing factor, our results showed
that Bmi-1 has a positively regulatory effect on miR-21
and miR-34a, indicating the existence of an intermediate
link in such a regulatory effect on miR-21 and miR-34a.
Previous studies have shown that Bmi-1 can increase the
NF-kB activity [39], and the miR-21 and miR-34a pro-
moter region has the NF-kB binding site [40]. Based on
these findings, we assumed that Bmi-1 may regulate the
expression of miR-21 and miR-34a via NF-kB. Firstly, we
utilized dual luciferase report gene assay to detect the
NF-kB transcriptional activity after exogenous change in
Bmi-1 expression and found that after upregulation of
Bmi-1 in SGC7901 cells, the NF-kB transcription activity
was enhanced significantly; and after downregulation of
Bmi-1 in MKN45 cells, the NF-kB transcription activity
was decreased significantly (Fig. 7a). As the NF-kB activ-
ity is related to its aggregation in cell nucleus, we used
Western blot to measure the relative content of NF-kB
subunit p65 after extraction of the nucleus protein and
plasma protein, in order to detect changes in the intra-
cellular distribution of p65. After Bmi-1 overexpression
in SGC7901 cells, the p65 level in the nucleus was in-
creased; while after Bmi-1 interference in MKN45 cells,
the p65 level in the nuclear was decreased (Fig. 7b).
These results confirmed that Bmi-1 can promote the
NF-kB aggregation in nuclear and activate its transcrip-
tion activity in gastric cancer cells. Then, we validated
whether the NF-kB may bind to miR-21 and miR-34a
promoter by ChIP test. Results showed that p65 do bind
to the promoter region of miR-21 and miR-34a, and
after Bmi-1 overexpression in SGC7901 cells, the bind-
ing of p65 to the miR-21 and miR-34a promoter region
was significantly increased (left panel of Fig. 7c, d), while
after Bmi-1 interference in MKN45 cells, the binding of
p65 to the miR-21 and miR-34a promoter region was
decreased significantly (right panel of Fig. 7c, d), indicat-
ing that Bmi-1 may increase the binding of p65 to the
miR-21 and miR-34a promoter region. Furthermore, we
used the NF-kB inhibitor pyrrolidine dithiocarbamate
(PDTC) to treat SGC7901 cells overexpressing Bmi-1
and found PDTC treatment can inhibit the increase of
miR-21 and miR-34a expression induced by Bmi-1 overex-
pression (Fig. 7e).These results suggested that Bmi-1 regu-
lates the expression of miR-21 and miR-34a via NF-kB.
Bmi-1 regulates N F-kB-miR-21/miR-34a via activating AKT
In the above-mentioned experiments, we found that Bmi-1
downregulates PTEN and upregulates pAKT (Fig. 8a).
Since PTEN is a well-known target gene of miR-21[32],
Bmi-1 may regulate PTEN via miR-21. Previous studies
have also shown that Bmi-1 may inhibit the expression of
PTEN by direct binding to the PTEN promoter in nasopha-
ryngeal carcinoma cells [41]. So, we conducted ChIP test to
verify whether Bmi-1 may bind to the PTEN promoter in
gastric cancer cells. The results showed that Bmi-1 really
binds to the PTEN promoter region, which were similar to
those in previous study [41] (Fig. 8b), suggesting that Bmi-1
may directly inhibit the expression of PTEN and thereafter
activate AKT.
It has been reported that AKT can activate NF-kB [42],
so we suspected that Bmi-1 may regulate NF-kB and miR-
21/miR-34a via activating AKT. First, we overexpressed
AKT in Bmi-1 knockdown cells or control cells and found
that activated AKT can increase phosphalated p65(pp65),
which is activated p65 protein, enhance the aggregation of
p65 in cell nucleus, and activate NF-kB transcriptional ac-
tivity and can also reverse the decreased pp65 and NF-kB
transcriptional activity induced by Bmi-1 knockdown
(right panels of Fig. 8c, d, lower panel of Additional file 10:
Figure S6); meanwhile, AKT inhibitor MK-2206 treatment
can inhibit the increased pp65, aggregation of p65 in cell
nucleus and NF-kB transcriptional activity induced by
Bmi-1 overexpression (left panels of Fig. 8c, d, upper panel
of Additional file 10: Figure S6), suggesting that Bmi-1
activates NF-kB via AKT. Further, we found that over-
expression of AKT increased the expression of miR-21 and
miR-34a and can also reverse the decreased expression of
miR-21 and miR-34a induced by Bmi-1 knockdown; mean-
while, AKT inhibitor treatment can inhibit the increased
(See figure on previous page.)
Fig. 5 miR-34a negatively regulates stem cell-like properties of gastric cancer cells. a Expression of miR-34a was decreased in microsphere of
MKN45 cells. Fold change of miR-34a in spheroid cells (SC) and parental cells (PC) was analyzed by QRT-PCR. b miR-34a overexpression inhibits
cell growth in MNK45 cells. Cells growth was detected by CCK-8 in miR-34a overexpressing cells (miR-34a) and control cells (Con). c miR-34a
overexpression inhibits proliferation in MNK45 cells. Proliferation ability of cells was detected by colony formation assay, then photographed
(upper panel) and quantified (lower panel). d miR-34a overexpression decreases microsphere formation in MKN45 cells. Microsphere formation
was tested by serum-free suspension culture (upper panel) and quantified (lower panel) in miR-34a overexpressing cells (miR-34a) and control
cells (Con). e miR-34a overexpression inhibits migration ability in MNK45 cells. Migration ability of cells was detected by Transwell Assay and
then photographed (upper panel) and quantified (lower panel). f miR-34a overexpression decreases drug resistance to EPI in MKN45 cells. Cell
viability after treatment with increasing doses of drug for 48 h was determined with CCK-8. g miR-34a overexpression in MKN45 cells after
infecting by lentivirus containing miR-34a was confirmed by QRT-PCR. Error bars in all panels represent the mean ± SD (*P < 0.05, **P < 0.01 as
compared with control)
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expression of miR-21 and miR-34a induced by Bmi-1 over-
expression (Fig. 8e), indicating that Bmi-1 upregulates
miR-21 and miR-34a via activating AKT.
Discussion
Over the past two decades, research on CSCs has attracted
great interest and also made great progress. As an oncogene
and stem cell marker, Bmi-1 can maintain the self-renewal of
CSCs in some tumors, including breast cancer and glioma,
but whether Bmi-1 is implicated in the regulation of gastric
CSCs is still unclear. In this study, we isolated stem cell-like
cells by serum-free microsphere culture and found that Bmi-
1 was overexpressed in microsphere cells. Furthermore,
Bmi-1 overexpression increased microsphere formation rate,
anti-cancer drug resistance, cell migration, and stem cell
markers expression, while Bmi-1 knockdown decreased
these parameters in GC cells Clinical samples analysis
showed that Bmi-1 expression in GC tissues was associated
with regional lymph node metastasis and distant ovary me-
tastasis and positively correlated with the expression of stem
cell markers. These results suggested that Bmi-1 positively
regulates the stem cell-like characteristics of GC cells.
Bmi-1 is a transcriptional inhibitor and the earliest re-
search found that Bmi-1 downregulated the expression
of p16 and p19 by inhibiting INK4a/ARF and thus regu-
lates cell proliferation and senescence [29]. Douglas
et al. found that Bmi-1 may promote the development of
Ewing’s sarcoma through p16 independent mechanisms,
and Bmi-1 knockdown induced expression changes of
hundreds of downstream genes [30]. We previously found
that Bmi-1 can influence breast cancer cells proliferation
and tumorigenicity through regulating pAKT [31]. Song
et al. found that Bmi-1 may inhibit PTEN expression, then
activate PI3K/AKT/Snail pathway and therefore regulate
EMT and metastasis of nasopharyngeal cancer cells [41].
These results indicated that Bmi-1 may play its role by
regulating many downstream target genes. However, the
mechanisms of Bmi-1 have not been fully elucidated, espe-
cially in regulating stemness.
miRNAs plays important roles in the process of cell
proliferation, apoptosis, and carcinogenesis by interacting
with mRNAs, IncRNAs, and other endogenous RNAs
[43, 44]. Recently, some studies suggested that miRNAs
were involved in regulation of CSCs. We speculated that
Bmi-1, as an exogenous gene-silencing factor, might also
regulate the expression of a variety of genes via miRNAs
and found that miR-21, miR-34a, and miR-125a-5p were
regulated by Bmi-1. Of these three miRNAs, miR-21 was
most significantly affected by Bmi-1. In gastric cancer tis-
sues, miR-21 had a significantly positive correlation with
Bmi-1 expression. It was reported that miR-21 is highly
expressed in many kinds of malignant tumor tissues and
might act as an oncogene [45]. In breast cancer and colo-
rectal cancer, miR-21 is involved in regulation of EMTand
stemness [46, 47]. In gastric cancer, overexpression of
miR-21 promotes cell growth, invasion, drug resistancem
and EMT by inhibiting PTEN and P53 [48, 49]. It has also
been found that miR-21 expression in gastric CSCs is
higher than in parental cells [50]. In our study, in vitro ex-
periments found that miR-21 was highly expressed in
microsphere which enrich stem cell-like cells, and it may
enhance the self-renewal, drug resistance, migration, and
stem cell markers expression in GC cells, and clinical sam-
ple investigation found that miR-21 was highly expressed
in GC tissues and positively correlated with lymph node
metastasis and nerve invasion. These results suggested
miR-21 positively regulates stem cell-like properties of GC
cells. Further, we conducted co-transfection to simultan-
eously change the expression of Bmi-1 and miR-21 and
found that upregulation of miR-21 restored the stem
cell-like characteristics of GC cells inhibited by Bmi-1
knockdown; and downregulation of miR-21 inhibited the
enhancement of stem cell-like characteristics induced by
Bmi-1 overexpression. Therefore, it confirmed that miR-
21 may mediate the function of Bmi-1 in regulating the
stem cell-like characteristics of GC cells. Since miR-21
may regulate the expression of a variety of downstream
target genes, Bmi-1 may form a complex regulatory net-
work via miR-21. We tested two important downstream
target genes of miR-21, p53 and PTEN, and did find
(See figure on previous page.)
Fig. 6 MiR-34a negatively regulates stem cell-like characteristics of gastric cancer cells by downregulating Bmi-1. a Expression of Bmi-1 and c-Myc
was suppressed by miR-34a, while overexpression of c-Myc increased the inhibited expression of Bmi-1. The expression of c-Myc, Bmi-1, and
β-actin in the cell lysis was analyzed by Western blot. b Overexpression of Bmi-1 reversed the inhibition of proliferation ability(colony formation)
induced by miR-34a upregulation in MKN45 cells and then photographed (upper panel) and quantified (lower panel). c Overexpression of Bmi-1
reversed the inhibition of microsphere formation induced by miR-34a upregulation. Microsphere formation was tested by serum-free suspension
culture (upper panel) and quantified (lower panel) in control cells (vector), miR-34a overexpressing cells(miR-34a), cells simultaneously overexpressing Bmi-1
and miR-34a (miR34a+Bmi-1), and Bmi-1 overexpressing cells (Bmi-1). d Overexpression of Bmi-1 reversed the inhibition of migration ability induced by
miR-34a upregulation in MKN45 cells. Migration ability of cells was detected by Transwell Assay and then photographed (upper panel) and quantified
(lower panel). e Overexpression of Bmi-1 reversed the inhibition of drug resistance induced by miR-34a upregulation in MKN45 cells. Cell viability after
treatment with increasing doses of drug EPI for 48 h was determined with CCK-8. f and g Bmi-1 overexpression in MKN45 cells was confirmed by Western
blot (f) and miR-34a overexpression in MKN45 cells after infecting by lentivirus containing miR-34a was confirmed by QRT-PCR (g) in control cells (con),
miR-34a overexpressing cells (miR-34a), cells simultaneously overexpressing Bmi-1 and miR-34a (miR34a+Bmi-1) and Bmi-1 overexpressing cells (Bmi-1) .
Error bars in all panels represent the mean ± SD (*P< 0.05, **P< 0.01)
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Bmi-1 may regulate the downstream p53 and PTEN-
AKT pathways via miR-21. Previous studies have shown
that Bmi-1 may directly bind to PTEN promoter in
nasopharyngeal carcinoma cells [41]. In this study, we
also found that Bmi-1 binds to PTEN promoter in GC
cells, suggesting Bmi-1 may directly inhibit the expression
of PTEN. Taken together, these results suggested that in
addition to the direct effect, Bmi-1 may indirectly regulate
PTEN-AKT via miR-21 therefore forming bypass path-
ways to enhance its activating effect on AKT.
MiR-34a acts as a tumor suppressor and is downregu-
lated in some kinds of cancer [51, 52]. It negatively regu-
lates stem cell-like characteristics of glioma cells through
downregulating c-Met and NOTCH [53] and inhibits the
Fig. 7 Bmi-1 regulates the expression of miR-21 and miR-34a via NF-kB. a Bmi-1 overexpression increases NF-kB transcriptional activity in SGC7901 cells,
and Bmi-1 knockdown reduces NF-kB transcriptional activity in MKN45 cells. Gastric cancer cells were co-transfected with pNF-kB-luciferase plasmid and
pRL-TK renilla plasmid, and transcriptional activity of NF-kB was tested by luciferase reporter activity assays. b Bmi-1 overexpression induces NF-kB
aggregation in nuclear of SGC7901 cells, and Bmi-1 knockdown decreases NF-kB aggregation in nuclear of MKN45 cells. Cytoplasmic(C) and nuclear (N)
proteins of cells were extracted and detected by Western blot. Nuclear protein TBP was used as a nuclear protein internal control and β-actin was as a
loading control. c Bmi-1 overexpression promotes the binding of p65 to miR-21 promoter region in SGC7901 cells, and Bmi-1 interference reduces the
binding of p65 to miR-21 promoter region in MKN45 cells. The binding of p65 to miR-21 promoter was analyzed by ChIP in gastric cancer cells with
changed Bmi-1 expression level. The ChIP-enriched DNA analyzed by QRT-PCR was normalized to input DNA, followed by subtracting nonspecific
binding determined by control IgG. d Bmi-1 overexpression promotes the binding of p65 to miR-34a promoter region in SGC7901 cells, and
Bmi-1 interference reduces the binding of p65 to miR-34a promoter region in MKN45 cells. The binding of p65 to miR-34a promoter was
analyzed by ChIP in gastric cancer cells with changed Bmi-1 expression level. The ChIP-enriched DNA analyzed by QRT-PCR was normalized to
input DNA, followed by subtracting nonspecific binding determined by control IgG. e NF-kB inhibitor PDTC treatment inhibits the increase of
expression of miR-21 and miR-34a induced by Bmi-1 overexpression in SGC7901 gastric cancer cells. Fold changes of miR-21 and miR-34a in
control vector transfected cells (vector), Bmi-1 overexpressing cells (Bmi-1), and Bmi-1 overexpressing cells treated with NF-kB inhibitor PDTC
(Bmi-1+PDTC) was analyzed by QRT-PCR. Error bars in all panels represent the mean ± SD (*P < 0.05, **P < 0.01)
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growth, invasion and metastasis of GC by targeting
PDGFR and MET [51]. In present study, we found that
miR-34a is downregulated in GC tissues and negatively
correlates with aggressive tumor phenotype. Furthermore,
in vitro studies showed that miR-34a inhibited cells prolif-
eration and microsphere formation, decreased drug resist-
ance, and migration potential. These results suggested that
miR-34a acts as a tumor suppressor, and negatively regu-
lates stem cell-like characteristics in GC cells. However,
why Bmi-1 upregulates miR-34a which has opposite func-
tions? We conceived there might be a negative feedback
pathway between Bmi-1 and miR-34a and Bmi-1 inhibit
its own overexpression and functions by inducing miR-34a.
It was reported that c-Myc is a target gene of miR-34a [37],
and c-Myc binds to t Bmi-1 promoter and upregulates its
expression. Therefore, miR-34a may regulate Bmi-1 via
c-myc. Our experiments showed that after miR-34a up-
regulation, Bmi-1 and c-Myc expression was inhibited,
while c-Myc overexpression increased the inhibited ex-
pression of Bmi-1, confirming miR-34a downregulates
Bmi-1 by targeting c-Myc. Further, we found that Bmi-
1 overexpression restored stem cell-like characteristics
inhibited by miR-34a upregulation. These results con-
firm our assumption that miR-34a negatively regulates
stem cell-like characteristics of GC cells by negative
feedback regulation of Bmi-1. The complicated negative
feedback loop can also explain why we did not found
the correlation between the expression of Bmi-1 and
miR-34a in GC tissues. In addition, our study found a new
mechanism and pathway by which miR-34 negatively reg-
ulates stemness through downregulating Bmi-1.
What is the mechanism of Bmi-1 to regulate miR-21
and miR-34a? Studies have shown that Bmi-1 regulates
NF-kB activity by influencing its nuclear-plasma distribu-
tion [39, 54], and NF-kB can binds to the promoter region
of miR-21 and miR-34a [40, 55] . Thus, we hypothesized
that Bmi-1 may regulate miR-21 and miR-34a through acti-
vating NF-kB. In our study, reporter assay and western ana-
lysis confirmed that Bmi-1 may increase NF-kB aggregation
in cell nucleus and activate its transcriptional activity. ChIP
test confirmed the binding of NF-kB to miR-21 and miR-
34a promoter, and Bmi-1 increases the binding. Further-
more, NF-kB inhibitors can inhibit the upregulation of
miR-21 and miR-34a induced by Bmi-1 overexpression.
These data confirmed Bmi-1regulates miR-21 and miR-34a
expression via activating NF-kB. Further, as it was found
that AKT can activate NF-kB, we suspected Bmi-1 may
regulate NF-kB and miR-21/miR-34a via activating AKT.
We found that AKT overexpression can really activate NF-
kB and increase miR-21/miR-34a expression, while AKT
inhibitor treatment can inhibit the increased NF-kB activity
and upregulation of miR-21 and miR-34a induced by
Bmi-1 overexpression, indicating that Bmi-1 upregulates
NF-kB activity and miR-21/miR-34a expression via activat-
ing AKT.
Conclusions
In conclusion, Bmi-1 positively regulates stem cell-like
properties in GC cells via upregulating miR-21. Bmi-1
directly binds to PTEN promoter and regulates PTEN/
AKT and indirectly regulates PTEN/AKT via miR-21
therefore forming bypass pathways to enhance its acti-
vating effect on AKT. MiR-34a negatively regulates stem
cell-like characteristics by negative feedback regulation
of Bmi-1. Bmi-1 upregulates miR-21/miR-34a expression
by activating AKT-NF-kB pathway. Thus, we clarify a new
mechanism and complex regulation pathway (Fig. 8f) by
which Bmi-1 regulates stem cell-like characteristics of
GC cells.
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Fig. 8 Bmi-1 regulates NF-kB - miR-21/miR-34a via activating AKT. a Bmi-1 overexpression downregulates the expression of PTEN and increases
the expression of phosphalated AKT (pAKT) in SGC7901 cells (left panel), and Bmi-1 knockdown upregulates the expression of PTEN and decreases
the expression of pAKT in MKN45 cells (right panel). The expression of Bmi-1, PTEN, pAKT, and total AKT (tAKT) was analyzed by Western blot in
gastric cancer cells. b Bmi-1 overexpression promotes the binding of p65 to the PTEN promoter region in SGC7901 cells. The binding of Bmi-1 to
PTEN promoter was detected by ChIP in SGC7901 cells. The p16 promoter was used as positive control and GAPDH as negative control. c AKT in-
hibitor MK-2206 treatment reduces the expression of phosphalated p65 (pp65) induced by Bmi-1 overexpression (left panel), and activated AKT
can increase the expression of pp65 inhibited by Bmi-1 knock down (right panel). The effect of Bmi-1 and AKT on pp65 and total p65 expression
was tested by Western blot. d AKT inhibitor MK-2206 treatment suppresses NF-kB transcriptional activity induced by Bmi-1 overexpression
(left panel), and activated AKT promotes NF-kB transcriptional activity inhibited by Bmi-1 knock down (right panel). Transcriptional activity of NF-kB
in gastric cancer cells was tested by luciferase reporter activity assays. e AKT inhibitor MK-2206 treatment inhibits the expression of miR-21 and
miR-34a induced by Bmi-1 overexpression (left panel), and activated AKT increases the expression of miR-21 and miR-34a inhibited by Bmi-1 knock
down (right panel). Fold change of miR-21 and miR-34a in gastric cancer cells was analyzed by QRT-PCR. f Schematic representation of the
molecular mechanisms and regulation pathways in Bmi-1 regulating gastric cancer stem cell-like properties. Error bars in all panels represent the
mean ± SD (*P < 0.05, **P < 0.01)
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